(Q29615809)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

30 April 2017

author name string

Liu P

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

30 April 2017

Cheng H

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

30 April 2017

Roberts TM

3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

30 April 2017

Zhao JJ

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

August 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

Nature Reviews Drug Discovery

30 April 2017

published in

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

30 April 2017

volume

8

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

30 April 2017

issue

8

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

30 April 2017

page(s)

627-44

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

30 April 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Targeting cancer with small molecule kinase inhibitors

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Somatic mutations affect key pathways in lung adenocarcinoma

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

An integrated genomic analysis of human glioblastoma multiforme

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Targeting phosphoinositide 3-kinase: moving towards therapy

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The genomic landscapes of human breast and colorectal cancers

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Defining the role of mTOR in cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

AKT/PKB signaling: navigating downstream

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The tuberous sclerosis complex

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

mTOR and cancer: insights into a complex relationship

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Current development of mTOR inhibitors as anticancer agents

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

TOR signaling in growth and metabolism

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Exploiting the PI3K/AKT pathway for cancer drug discovery

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

PI 3-kinase p110beta: a new target for antithrombotic therapy

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Upstream and downstream of mTOR

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The biology and clinical relevance of the PTEN tumor suppressor pathway

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

High frequency of mutations of the PIK3CA gene in human cancers

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A central role for JNK in obesity and insulin resistance

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307)

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The PI3K-PDK1 connection: more than just a road to PKB

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

30 April 2017

Phosphoinositide kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Pten is essential for embryonic development and tumour suppression

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A novel AKT3 mutation in melanoma tumours and cell lines

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

PTEN-deficient cancers depend on PIK3CB.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Class 1A PI3K regulates vessel integrity during development and tumorigenesis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Tenets of PTEN tumor suppression

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The regulation and function of Class III PI3Ks: novel roles for Vps34.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A new mutational AKTivation in the PI3K pathway

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The p110alpha isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Hsp90: a novel target for cancer therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Cancer-specific mutations in PIK3CA are oncogenic in vivo

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Oncogenic PI3K deregulates transcription and translation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The Akt-mTOR tango and its relevance to cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Restraining PI3K: mTOR signalling goes back to the membrane.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

3 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

3 June 2018

https://api.crossref.org/works/10.1038%2FNRD2926

The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt.

31 March 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Human cancer, PTEN and the PI-3 kinase pathway

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Clinical role of positron emission tomography in oncology

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Tangled webs: evidence of cross-talk between c-Raf-1 and Akt.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

PKB/AKT: functional insights from genetic models

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Therapeutic monitoring of rapamycin: a new immunosuppressive drug.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Chemically targeting the PI3K family

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

High-throughput oncogene mutation profiling in human cancer

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3142564

Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse

26 November 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Biochemistry. PI3K charges ahead

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

D-21266, a new heterocyclic alkylphospholipid with antitumour activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

PIK3CA mutation and amplification in human lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

PIK3CA gene amplification in Japanese non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

PIK3CA as an oncogene in cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Amplicon profiles in ovarian serous carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

PIK3CA alterations in primary (de novo) and secondary glioblastomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

AKT1(E17K) in human solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Identification of PTEN mutations in metastatic melanoma specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Analysis of PTEN and the 10q23 region in primary prostate carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

PTEN/MMAC1/TEP1 involvement in primary prostate cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Essential role for the p110delta phosphoinositide 3-kinase in the allergic response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinositide 3-kinase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Phosphatidylinositol 3-kinase regulates the CD4/CD8 T cell differentiation ratio

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

p110γ and p110δ Phosphoinositide 3-Kinase Signaling Pathways Synergize to Control Development and Functions of Murine NK Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCλ/ζ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2926

PI3 kinases in cancer: from oncogene artifact to leading cancer target

31 March 2020

1 reference

https://pubmed.ncbi.nlm.nih.gov/19644473

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

30 April 2017

Dimensions Publication ID

1043430958

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

2 references

30 April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19644473

PubMed publication ID

2 references

30 April 2017